Publications

Investigational new drugs

Extrahepatic metabolism of ibrutinib.

01-02-2021

Journal of pharmaceutical and biomedical analysis

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

15-06-2024

Molecular pharmaceutics

Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.

01-04-2024

Toxicology and applied pharmacology

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.

26-03-2024

Cancer chemotherapy and pharmacology

Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.

08-03-2024

Cancer drug resistance (Alhambra, Calif.)

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel.

06-02-2024

Cancer chemotherapy and pharmacology

Are novel oral oncolytics underdosed in obese patients?

01-02-2024

Journal of clinical pharmacology

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

01-02-2024

Therapeutic drug monitoring

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.

01-02-2024

Clinical pharmacology and therapeutics

A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.

01-02-2024

Journal for immunotherapy of cancer

No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC.

31-01-2024

Therapeutic drug monitoring

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

30-01-2024

International journal of pharmaceutics

Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.

25-01-2024

Clinical and translational science

Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.

01-01-2024

FEBS open bio

Acquired and intrinsic resistance to vemurafenib in BRAF^V600E -driven melanoma brain metastases.

01-01-2024

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of an LC-MS/MS method for the quantification of KRAS^G12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study.

01-01-2024

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.

10-12-2023

Clinical and translational science

The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib.

01-12-2023

CPT: pharmacometrics & systems pharmacology

Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk.

01-12-2023

Pharmaceutical research

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

01-12-2023

The New England journal of medicine

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

09-11-2023

Biomedical chromatography : BMC

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

01-11-2023

Journal of pharmaceutical and biomedical analysis

Validated LC-MS/MS method for simultaneous quantification of KRAS^G12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

25-10-2023

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

High accumulation of nivolumab in human breast milk: A case report.

01-10-2023

British journal of clinical pharmacology

Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function.

01-10-2023

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Pharmacokinetics of the KRAS^G12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

01-10-2023

EJNMMI physics

Predicting [¹⁷⁷Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [⁶⁸Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling.

24-08-2023

Clinical pharmacokinetics

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.

01-08-2023

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development.

01-08-2023

Die Pharmazie

Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).

01-08-2023

Pharmaceutical research

P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice.

01-08-2023

Gynecologic oncology

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.

01-07-2023

Clinical pharmacokinetics

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach.

01-07-2023

Biomedical chromatography : BMC

Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs.

01-07-2023

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins.

01-06-2023

Cancer chemotherapy and pharmacology

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

01-06-2023

Therapeutic drug monitoring

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa.

01-06-2023

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Redispensing of expensive oral anticancer medicines: A practical application.

16-05-2023

Pharmaceutical research

Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer.

01-05-2023

Molecular pharmaceutics

Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.

01-05-2023

Pharmacological research

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs.

01-04-2023

Cancer chemotherapy and pharmacology

Assay performance and stability of uracil and dihydrouracil in clinical practice.

01-03-2023

Journal of pharmaceutical and biomedical analysis

A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling.

20-02-2023

EJNMMI research

A physiologically based pharmacokinetic model for [⁶⁸Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients.

03-02-2023

Clinical and translational science

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens.

01-02-2023

Anti-cancer drugs

Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors.

01-02-2023

Acta pharmaceutica Sinica. B

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism.

01-02-2023

The New England journal of medicine

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

08-12-2022

Clinical pharmacokinetics

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.

01-12-2022

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.

15-11-2022

Extrahepatic metabolism of ibrutinib.

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice.

The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib.

Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment.

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel.

Are novel oral oncolytics underdosed in obese patients?

Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam.

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.

A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.

No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC.

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.

Predictability of human exposure by human-CYP3A4-transgenic mouse models: A meta-analysis.

Acquired and intrinsic resistance to vemurafenib in BRAFV600E -driven melanoma brain metastases.

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study.

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.

The use of microtracers in food-effect trials: An alternative study design for toxic drugs with long half-lives exemplified by the case for alectinib.

Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk.

Cortisol as Biomarker for CYP17-Inhibition is Associated with Therapy Outcome of Abiraterone Acetate.

Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.

Development and validation of an HPLC-MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue-related matrices.

Validated LC-MS/MS method for simultaneous quantification of KRASG12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

High accumulation of nivolumab in human breast milk: A case report.

Optimizing carboplatin dosing by an improved prediction of carboplatin clearance using a CT-enhanced estimate of renal function.

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling.

Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development.

Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).

P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice.

WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.

Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach.

Bioanalytical methods for pharmacokinetic studies of antileishmanial drugs.

The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins.

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.

Development of a Therapeutic Drug Monitoring Strategy for the Optimization of Vincristine Treatment in Pediatric Oncology Populations in Africa.

Redispensing of expensive oral anticancer medicines: A practical application.

Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer.

Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice.

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs.

Assay performance and stability of uracil and dihydrouracil in clinical practice.

A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling.

A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients.

A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens.

Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumors.

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism.

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.

Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue.

This site uses cookies

Acquired and intrinsic resistance to vemurafenib in BRAF^V600E -driven melanoma brain metastases.

Development and validation of an LC-MS/MS method for the quantification of KRAS^G12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study.

Validated LC-MS/MS method for simultaneous quantification of KRAS^G12C inhibitor sotorasib and its major circulating metabolite (M24) in mouse matrices and its application in a mouse pharmacokinetic study.

Pharmacokinetics of the KRAS^G12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c.

Predicting [¹⁷⁷Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [⁶⁸Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling.

A physiologically based pharmacokinetic model for [⁶⁸Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients.